Vascular Morbidity and Mortality in Craniopharyngioma Patients—A Scoping Review.

Author(s): Julia Beckhaus [1,2]; Carsten Friedrich [1]; Hermann L. Müller (corresponding author) [1,*]

1. Introduction

Located in the sellar and parasellar regions, craniopharyngiomas (CPs) describe rare, benign tumors (WHO grade 1), registering approximately 0.5 to 2 new cases per million people per year [1,2]. Among pediatric patients (patients under 18 years old), the adamantinomatous type (ACP) is the most common non-neuroepithelial intracranial tumor, representing approximately 5–11% of such tumors in this age group—the papillary type is more common in adults [3,4]. The age distribution has two peaks: one in children aged 5 to 15 years old and another in adults aged 50 to 70 years old [1].

Treatment often involves surgical resection using trans-sphenoidal or transcranial approaches, emphasizing hypothalamus-sparing surgical strategies [5]. Both the hypothalamus and the optic chiasm and critical neurovascular structures (f.e. arterial circle of Willis) are located in the surgical field. Vasospasm and further vascular complications are rare post-tumor resection complications [6]. After incomplete resection or if relapse or progress occurs, CP patients are often treated with radiotherapy [7]. High-precision photon therapy and proton beam therapy precisely target the (residual) tumor while protecting the surrounding structures and tissues [8]. Nonetheless, radiotherapy’s long-term adverse effects include vascular complications such as Moyamoya disease [9]. Moyamoya disease occurs in children and adult survivors of pediatric brain tumors and increases the risk of cerebrovascular events [10].

Due to their proximity to hypothalamic structures and the pituitary gland, both hypothalamic infiltration and surgical damage to the hypothalamic–pituitary axes (HPA) can cause hormonal and neuroendocrine dysfunction [11]. In patients with hypothalamic involvement and surgical hypothalamic lesions, BMI typically increases in the first year after surgery [12]. Neuroendocrine deficits, combined with hypothalamic damage, are covered by the umbrella term hypothalamic syndrome [13], which is an i.a. characterized by uncontrolled eating and morbid obesity [14]. Childhood obesity is related to adult cardiovascular disease (CVD) risk factors [15]. Thus, hypothalamus-involving CP patients have a lower 20-year overall rate of survival [16]. In general, adults who experienced childhood or young adult cancers have a 10-fold higher risk of experiencing stroke than their healthy siblings [17]. Severe obesity increases the risk of cardiovascular complications and may reduce life expectancy compared to those of healthy individuals of the same age [13,18,19]. Childhood-onset CP survivors must navigate decades of survival and need tailored treatment and multidisciplinary approaches to reduce the risk of late morbidity due to vascular sequela related to CP diagnosis and treatment [20].

This scoping review analyzes and summarizes the available evidence regarding vascular morbidity in CP patients at risk of experiencing problems related to the tumor, surgery, irradiation, or long-term sequela due to obesity or lifestyle factors. Due to the disease’s rareness and the resulting scarcity of data, a scoping review was the most appropriate method to review the existing studies and case reports. The review question sought to identify the quantity and types of vascular morbidity in adult and pediatric patients with childhood- and adult-onset CP in existing case reports and observational studies.

2. Materials and Methods

This scoping review was conducted in accordance with the JBI methodology for scoping reviews [21]. The review was not registered. This review was performed in accordance with the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines.

2.1. Eligibility Criteria

The eligibility criteria for the record assessment process are described within the population, concept and context (PCC) framework (Table 1).

2.2. Types of Sources

This scoping review regarded case reports and observational studies as retrospective cohort studies and cross-sectional studies. No literature or narrative reviews were considered for inclusion.

2.3. Search Strategy

Our search strategy was devised to locate published and peer-reviewed studies. Initially, a restricted explorative search of Medline was performed to identify relevant articles on this topic. Terms extracted from the titles and abstracts of relevant articles, along with index terms characterizing the articles, were used to develop a full search strategy for Medline, CINAHL, and Web of Science (Appendix A). The search strategy, including all identified index terms and keywords, was adapted for each database. Additionally, the reference list outlining all included sources of evidence was screened to identify further studies.

English- and German-language studies were included. Studies published before 1990 were excluded to reflect recent progress in imaging techniques, diagnostics, and treatment development. The searched databases were Medline, CINAHL, and Web of Science. All English- or German-language published up to 19 June 2023 were reviewed.

2.4. Study/Source of Evidence Selection

Following this search, all identified citations were collated and uploaded to EndNote version 20 (Clarivate Analytics, Philadelphia, PA, USA), and any duplicate studies were removed. Titles and abstracts were screened by two independent reviewers (JB and CF) for comparison with this study’s inclusion criteria. The full texts of the selected citations were compared to the inclusion criteria by two independent reviewers (JB and CF). Any disagreements between the reviewers at each stage of the selection process were resolved through the participation of an additional reviewer (HLM). The results of both the search and study inclusion process are shown in Figure 1.

2.5. Data Extraction

Data were extracted using a self-developed grid (Table S1). Results on reference, title, study type, study size, childhood- or adult-onset CP, study period, type of vascular complication, attributed etiology, time since CP treatment (follow-up), outcome parameters, and results were extracted from the included studies. This step was undertaken by one reviewer (JB) and supervised by two additional reviewers (CF and HLM).

3. Results

3.1. Characteristics of Included Studies

Our systematic search retrieved 514 records. In total, 107 of 514 records were included in our study after abstract and title screening. Ten articles were excluded because they were published before 1990. Seventy-two articles were included in this review after full-text screening was performed. The majority (n = 58) were case reports or case series. Only 14 studies were observational studies.

3.2. Vascular Morbidity and Mortality Analyzed in Observational Studies

Though all 14 observational studies investigated cardiovascular complications, only 3 of 14 observational studies also assessed post-CP neurovascular complications. One study focused on cerebral infarction [22]. The studied populations, exposures, comparisons, and outcomes of the included studies are summarized in Table 2. Studies with reported estimates were classified as observational studies. Both childhood- and adult-onset CP patients were studied. One study comparing childhood- and adult-onset CP assessed the CVD risk, showing that adult-onset CP patients have a higher CVD risk than childhood-onset CP patients [23]. Multiple exposures were investigated: metabolic syndrome (MetS)/obesity [24,25], hypothalamic involvement (HI) [26,27], and growth hormone substitution therapy [28].

In their studies, Jung et al. demonstrated that MetS and HI led to cardiac autonomic dysfunction, increasing the risk of cardiovascular events in CP patients [24,27]. In a multicenter cohort study of childhood-onset CP patients, a higher degree of obesity was correlated with increased left ventricular wall thickness [25]. Holmer et al. found that not only was HI an important risk factor for CVD in CP patients, but female CP patients were also at a higher risk of experiencing a CVD event [26]. Compared to patients with a nonfunctioning pituitary adenoma, no statistically significant difference in the incidence hazard ratio (Table 2) exists for CP patients receiving growth hormone treatment, according to the analysis by Verweij et al. [28].

Pereira et al. assessed the prevalence of cerebrovascular accidents (CVA), myocardial infarction (MI), and transient ischemic attacks (TIA) in CP patients [29]. Cerebrovascular morbidity was common in CP patients (14% CVA, 2% TIA, 6% MI). The authors demonstrated that CVA was most common (40%) in female, premenopausal, and estrogen-deficient patients [29]. In the German KRANIOPHARYNGEOM 2007 study, an 11% prevalence of cerebral infarction was identified in patients with childhood-onset CP between 2007 and 2019 [22]. In Merchant et al.’s study, childhood-onset CP patients were treated with limited surgery and proton beam therapy (PBT), and CP patients treated with surgery and photon irradiation therapy (XRT) were compared at follow-up regarding the occurrence of vasculopathies [8]. Vasculopathies occurred in both groups—14 cases (7 in each group) were recognized at follow-up. Three-year cumulative incidences of 3.98% (SE 1.96) for XRT patients and 4.49% (SE 2.21) for PBT patients were reported based on retrospective analyses. The 5-year cumulative incidence was calculated to be 4.99% (SE 2.19) for XRT patients and 7.87% (SE 2.87) for PBT patients. In another cohort study, 2 of 37 (5.4%) childhood-onset CP patients had asymptomatic vasculopathy identified at follow-up [30]. These patients were treated with adjuvant radiotherapy. Using a machine learning approach, Qian et al. reported that 30 (24.2%) of 371 CP patients experienced venous thromboembolism (VTE). Age, craniotomy, CSF leakage, and a long surgical duration were risk factors for VTE.

Three studies compared the CP study population to the general population of the respective country and calculated the standardized cardiovascular/circulatory disease mortality (SMR) or incidence rate (SIR) [31,32,33]. All three studies reported a statistically significant increase in circulatory disease-specific SMR in the respective Swedish and Dutch populations (Table 2). Olsson et al. also reported an increased SIR for cerebral infarction (7.1 (95% CI 5–9.9)) in Swedish childhood-onset CP patients [32]. Based on the observational studies, extensive HI, obesity, and female sex were circulatory disease risk factors in CP patients. Compared to the general population, CP patients had increased circulatory disease-specific incidence and mortality.

Table 2: Summary of the included observational studies.

Patient Population	Number of Cases	Exposure	Comparison	Outcome Parameters	Result	Ref.
Childhood-onset CP	53	MetS	No MetS	Cardiac autonomic function and heart rate	Patients with MetS: lower levels of SDNN, TP, RMSSD, and HF	[24]
Childhood-onset CP	48	HI	No HI	Cardiac autonomic function and heart rate	Patients with extensive HI: lower levels of SDNN, TP, and HF. No interaction between HI and obesity for HRV	[27]
Childhood-onset CP	36	Obesity	No obesity	Cardiac status: TTE parameters	Degree of obesity in CP is correlated with an increased left ventricular wall thickness (r = 0.645, p < 0.001)	[25]
Adult-onset CP	24	Adult-onset CP	Childhood-onset CP	CVD risk	Adult-onset CP was associated with a higher Framingham risk score, atherosclerotic CVD 10-year score, and lifetime risk score than childhood-onset disease	[23]
Childhood-onset CP on long-term GHT	42	HI	No HI	CVD risk	HI was an important CVD risk factor in CP patients; there was a higher risk of female patients with CP having CVA	[26]
Adult-onset CP	291	GHT	Patients with nonfunctioning pituitary adenoma	CVA and CVD	Incidence hazard ratio: CVA: 0.99 (0.19–5.10); CVD: 1.17 (0.57–2.39); death: 1.1 (0.21–5.69)	[28]
Childhood- or adult-onset CP at Leiden Medical Center (the Netherlands)	54	CP	No CP	CVA, myocardial infarction, and TIA	Prevalence: 22% total CV morbidity, 14% CVA, 2% TIA, 6% MI; CVA was more prevalent in premenopausal estrogen-deficient women; mortality: 40% were CV complications	[29]
Childhood-onset CP	244	Patients after surgery for CP with cerebral infarction	Patients after CP surgery without cerebral infarction	Cerebral infarction	Prevalence: 11% of CP patients were identified as having cerebral infarction (2007–2019)	[22]
Childhood-onset CP	94	CP patients with limited surgery and PBT	Patients with usual care (surgery and XRT)	Vasculopathy	7 in PBT and 7 in XRT with vasculopathy during follow-up; 3-year cumulative incidences of 3.98% (SE 1.96) [XRT] and 4.49% (SE 2.21) [PTB]; 5-year cumulative incidences of 4.99% (SE 2.19) [XRT] and 7.87% (SE 2.87) [PTB]	[8]
Childhood- and young adult-onset CP	37	Patients with upfront adjuvant XRT	Patients with incomplete surgical resection	Vasculopathy	2 (5.4%) children in the adjuvantXRT group developed asymptomatic radiation-related vasculopathies at follow-up	[30]
Adult-onset CP	371	CP	Other tumor entities	Venous thrombo-embolism	30 (24.2%) of 371 CP patients had VTE; patients with increased age, specific tumor pathology(CP and chordoma), craniotomy, CSF leakage,and a long surgical duration were at a higher risk of developing VTE	[34]
Childhood- or adult-onset CP	224	CP	General population in the Netherlands	Circulatory diseases	SMR circulatory diseases 2.3 (95% CI: 1.1–4.5) mainly due to CVD	[33]
Childhood- or adult-onset CP	307	CP	General population in Sweden	Circulatory diseases, ischemic heart disease, CVD	SMR circulatory diseases 3.6 (95% CI 2.1–5.7); SMR ischemic heart disease 3.6 (95% CI 1.6–6.8); SMR cerebrovascular 5.1 (95% CI 1.5–12); SIR cerebral infarction 7.1 (95% CI 5.0–9.9)	[32]
Childhood- or adult-onset CP at Lund University Hospital (Sweden)	60	CP	General population in Sweden	Cardiovascular and cerebrovascular mortality	SMR 3.21 (95% CI, 1.29–6.61)	[31]

Abbreviations: CVA: cerebrovascular accident; SDNN: standard deviation of all normal R-R intervals; TP: total power; RMSSD: root mean square of the difference of successive R-R intervals; HF: high frequency; HRV: heart rate variability; TIA: transient ischemic attack; SMR: standardized mortality rate; SIR: standardized incidence rate; GHT: growth hormone treatment; TTE: transthoracic echocardiography; HI: hypothalamic involvement; CI: confidence interval; PBT: proton beam therapy; CSF: cerebrospinal fluid; Ref: reference.

3.3. Vascular Morbidity and Mortality Analyzed in Case Reports

3.3.1. Neurovascular Sequela

Figure 2 summarizes the frequency of reported CP cases with neurovascular complications in the literature with regard to different associations. The fusiform dilatation of the carotid artery (FDCA) (n = 44) was the most frequently reported neurovascular complication, followed by vasospasm (n = 34), stroke (n = 30), Moyamoya disease (n = 26), aneurysm (n = 10), hemorrhage (n = 7), TIA (n = 6), and cavernoma (n = 5). Other rarer complications, with reported numbers under two cases, are not displayed. Associations either were surgery, irradiation, and the tumor itself or unspecified (Figure 2).

Figure 3 summarizes the short-, medium-, and long-term vascular complications of CP treatment via surgery and radiotherapy. Shortly after surgery (<1-year post-treatment), acute ischemic events and hemorrhage can occur. After radiotherapy, vasospasm and acute ischemic events were reported to be short-term complications (Figure 3). FDCA and aneurysm can be considered medium- or long-term consequences, occurring between one- and five-years post-surgery (Figure 3). Moyamoya syndrome and cavernoma are long-term complications following radiotherapy (more than 5 years post-treatment), whereas stroke/TIA and aneurysms are medium- to long-term complications of radiotherapy (Figure 3).

3.3.2. Fusiform Dilatations of the Carotid Artery (FDCA)

FDCA was the vascular complication most frequently reported (n = 44) in CP patients. FDCA describes an abnormal enlargement or widening of the carotid artery. FDCA can occur in the internal (ICA) and the external carotid arteries (ECA). In the included studies, both dilations (ICA and ECA) were described. It was apparent that FDCA mainly occurred in childhood-onset CP patients (Table 3). In the German childhood craniopharyngioma registry, a prevalence rate of 2.4% (14 of 583 CP patients) was calculated for FDCA between 2001 and 2015 [35]. The time interval between occurrence and treatment varied between 4 months and 12 years after treatment (Table 3). FDCA was attributed to surgery in 95% of patients (42 out of 44 cases) and irradiation in 2.3% of patients (1 case) (Figure 2). FDCA was mainly reported after the use of transcranial surgery (Table S2). Most patients did not present any clinical symptoms related to FDCA—headache was the initial symptom at FDCA diagnosis in three patients [36,37,38]. Due to carotid artery dilation, the disrupted blood flow could promote blood clots or emboli formation. Therefore, FDCA patients have an increased risk of stroke. However, for the cases reported in the literature, no ruptures or FDCA-related morbidity were described at follow-up.

3.3.3. Vasospasm

Vasospasm was the second most frequently reported vascular complication (34 cases) in the included studies (Table 3). Cerebral vasospasms were observed during or after surgical resection (transcranial or trans-sphenoidal approach) of CP (Figure 2) in both pediatric and adult patients (Table 3). In the included case studies, vasospasm was primarily described as a side effect of radiotherapy (26 of 34 cases) (Figure 2). Vasospasms were diagnosed at a time interval of between 5 days and 2 weeks after irradiation (Table 3).

3.3.4. Stroke/Transient Ischemic Attacks (TIA)

Overall, in 14 studies, 30 stroke cases and 6 TIA cases were reported in both childhood- and adult-onset CP patients (Table 3). Radiotherapy increases the risk of stroke and TIA (Figure 2). Stroke also occurred after surgery in six cases (Figure 2), following a transcranial approach (Table S2). The time interval between stroke and CP diagnosis/surgery varied between 10 days and 20 years post-CP diagnosis (Table 3). Accordingly, stroke should be regarded as both a short- and long-term complication of CP treatment.

3.3.5. Moyamoya Syndrome

Moyamoya syndrome was observed in 26 cases reported in 17 studies (Table 3). It mainly occurred in childhood-onset CP survivors. Moyamoya syndrome is a rare complication of irradiation treatment, affecting small blood vessels in the irradiated field. The arteries’ stenosis in Moyamoya syndrome has complications such as recurrent TIAs, stroke, seizures, and cognitive or developmental issues, though specific complications are dependent on the severity and location of the affected blood vessels. The occurrence interval for Moyamoya syndrome varied from 19 months to 30 years post-radiotherapy (Table 3). In most of the reported cases, information on long-term follow-up after Moyamoya disease diagnosis was lacking. Based on the included studies, no difference between photon and proton therapy was observed regarding the reported Moyamoya syndrome cases (Table S3).

3.3.6. Aneurysm

Unlike FDCA, aneurysms can involve more arterial vessels than just the carotid arteries. Aneurysms’ neuroradiological characteristics include arterial dilatations that do not have a fusiform shape, including saccular-shaped and “berry-like” arterial dilatations. Aneurysms were observed in 10 cases reported in six studies (Table 3). Aneurysms occurred in both childhood- and adult-onset CP patients. In adult-onset CP patients, aneurysms were side effects of surgery. In childhood-onset CP patients, aneurysms were diagnosed during an interval lasting between 8 months and 5 years after both surgical intervention and irradiation to treat CP (Table 3).

3.3.7. Hemorrhage

Hemorrhage was mainly reported in adult-onset CP patients, with only one case reported in childhood-onset CP patients (Table 3). Overall, only seven cases reported in six studies were observed. The reported hemorrhages were exclusively observed as immediate and intra- and perioperative surgical complications (Figure 2) [39,40]. Two studies reported hemorrhage cases after using a transcranial approach, while one study reported such a case after using a trans-sphenoidal approach (Table S2).

3.3.8. Cavernoma

In patients with non-CP brain tumors, radiotherapy is a known risk factor for cavernoma development [41]. Cavernoma was reported in five cases between 3 and 10 years after radio-oncological treatment of childhood-onset CP occurred (Table 3). The clinical courses of the cavernomas were benign—none of the reported patients developed a symptomatic hemorrhage [42,43]. However, children aged under 10 years old, when receiving irradiation, have an increased risk of developing cavernomas [42]. Although patients with cavernomas typically do not present clinical symptoms, hemorrhage is a serious complication. Magnetic resonance imaging (MRI), including magnetic resonance angiography (MRA), should be used consistently for extended follow-ups, especially in CP patients treated during early childhood [42].

3.3.9. Other Neurovascular Sequela

Other neurovascular complications included hematoma (two cases post-surgery), radiation-induced large vessel cerebral vasculopathy such as arterial stenosis and occlusion (two cases post-radiotherapy), pseudoaneurysm (one case after subtotal resection and radiotherapy), cerebroartherosclerosis (one case post-radiotherapy), and intracranial venous thrombosis (one case post-surgery for recurrence) (Table 3). Lucas et al.’s study reported 9 post-surgery stenosis cases and 22 stenosis cases post-PBT for childhood CP—3 patients presented with dilated perivascular space years after PBT [44]. Only hematoma was reported in both childhood- and adult-onset CP patients. All other complications only occurred in childhood-onset CP patients (Table 3).

Table 3: Reported cases with neurovascular complications.

Neuro-Vascular Complication	Number of Cases	Number of Reports	Time Interval since CP Treatment [Min–Max]	Childhood-/Adult-Onset	References
FDCA	44	13	4 months–12 years	Mainly child-hood-onset (two adult-onset)	[35,36,37,38,45,46,47,48,49,50,51,52,53]
Vasospasm	34	3	5 days–2 weeks after XRT	Both	[54,55,56]
Moyamoya syndrome	26	17	14.5 months–30 years	Mainly childhood-onset; two cases of adult-onset CP	[36,43,57,58,59,60,61,62,63,64,65,66,67,68,69,70]
Stroke/TIA	30 strokes 6 TIA	14	10 days after surgery–20 years post-CP diagnosis	Both	[44,63,65,66,70,71,72,73,74,75,76,77,78,79]
Hemorrhage	7	6	At surgery	Mainly adult-onset; one case of childhood-onset	[39,40,66,80,81,82]
Aneurysm	10	6	At surgery (adult); 8 months–5 years (children) 2 cases post-XRT (children)	Both	[43,44,83,84,85,86]
Cavernoma	5	3	3 years–10 years	Childhood-onset	[42,43,44]
Other	stenosis (31)dilated perivascular space (3)hematomas (2)RLVCV (2)pseudoaneurysm (1)cerebroartherosclerosis (1)intra-cranial venous thrombosis (1)	4	9 stenosis post-surgery cases and 22 post-PBT cases3 dilated perivascular space cases post-PBT5–63 months post-surgery (hematoma) 3.8 and 1-year post-XRT (RLVCV)5 months (pseudoaneurysm)26 years post-XRT (cerebroartherosclerosis) Immediately after surgery for recurrence (intracranial venous thrombosis)	Childhood-onset (hematoma: both)	[44,87,88,89,90]

Abbreviations: FDCA: fusiform dilatations of the carotid artery; RLVCV: radiation-induced large vessel cerebral vasculopathy; TIA: transient ischemic attack; XRT: irradiation; PBT: proton beam therapy; CP: craniopharyngioma.

3.4. Cardiovascular Sequela (Case Reports)

3.4.1. Cardiac Arrest

Probst et al. reported cardiac arrests observed during CP surgery in one childhood-onset CP case and one adult-onset CP case [91]. The two patients, 8 and 21 years old, were successfully reanimated during surgery after cardiac arrest.

3.4.2. Deep Venous Thrombosis and Pulmonary Embolism

Deep venous thrombosis (DVT) was observed in four cases reported in two studies [92,93]. The patients had childhood-onset CP and were diagnosed with DVT two weeks, two months, and 13 years after surgical CP treatment. The DVT was localized iliofemoral (two cases) and located in the lower extremity with extension into the inferior vena cava (one case). According to the authors, different pathophysiological pathways occurred in each patient: oral contraception and family history (16-year-old patient), post-surgical complication (13-year-old patient), and hypernatremic dehydration (5-year-old patient). One patient (10-year-old boy) experienced pulmonary embolism after DVT, occurring 25 days post-surgery, and veno-arterial extracorporeal membrane oxygenation (VA-ECMO) was required [93]. Another patient (4-year-old boy) experienced a bilateral pulmonary embolism on day 17 post-surgery.

4. Discussion

Vascular complications are rare events in CP patients. However, long-term circulatory disease-specific mortality and morbidity are higher in these patients compared to the general population. In the case reports identified for inclusion in this scoping review, FDCA and vasospasm were the most frequently observed neurovascular complications post-CP treatment. The included observational studies found abnormal echocardiographic values in CP patients associated with the degree of obesity [24,25]. CP survivors have higher circulatory disease-specific mortality and incidence compared to the studied general populations in several European countries [31,32,33]. The main risk factors for vascular morbidity and mortality observed in observational studies are extensive HI, female sex, and obesity [26]. Morbid obesity is a frequent sequela in patients with childhood-onset craniopharyngioma [12]. Patients with anterior and posterior HI and HL are at the highest risk of developing obesity [94]. Morbid obesity can result in MetS, a well-known risk factor for CVD. Long-term aftercare for this high-risk group of CP patients is needed for early diagnosis and the prevention of possible CVD events. Carotid artery, middle and anterior cerebral artery, posterior connecting artery, posterior cerebral artery, and basilar apex injuries were reported as intra- and perioperative vascular complications in CP. Due to these tumors’ tendency to encase in or adhere to both larger and smaller vessels, careful identification and microdissection of the tumor away from vessels is a key challenge of CP surgery. FDCA can occur immediately after surgery due to carotid manipulation or arterial wall weakening. Furthermore, aneurysm and hemorrhage can occur during surgery. Besides sparing the hypothalamic structures, surgeons should protect surrounding vessels to prevent vascular injuries. The best craniopharyngioma treatment approach typically includes a combination of strategies such as surgery, radiotherapy, and close monitoring. Furthermore, individual vascular complication risk factors increase the likelihood of an event. Consequently, vasculopathy development is multifactorial. Vasospasm, Moyamoya syndrome, and cavernoma were described as complications associated with radiotherapy. Vasospasm occurs shortly after radiotherapy (up to two weeks); Moyamoya syndrome can be a long-term complication of using radiotherapy to treat CP. One patient was diagnosed with Moyamoya syndrome 30 years after receiving CP treatment [59]. Usually, Moyamoya syndrome has no clinical symptoms. During follow-up, especially after radiotherapy, clinicians should be aware of this rare sequela and inform patients of their increased risk of experiencing neurovascular events due to Moyamoya syndrome.

Cavernomas can occur after radiotherapy treatment for brain tumors. Two childhood-onset CP cases with cavernoma were reported in the literature [42,43]. In a retrospective cohort of childhood cancer survivors treated with cranial radiotherapy, a minority of cavernomas (3 of 36 (8%) included patients) were classified as high risk for hemorrhage [41]. No symptomatic hemorrhage was reported in this cohort, and most individuals (92%) were classified as being at low risk of developing cavernoma [41]. However, more cases of radiotherapy-induced cavernoma with longer follow-ups are required to draw risk-related conclusions.

The implementation of MRA during and after CP treatment must be discussed. While FDCA, stroke/TIA, and aneurysms occur shortly after surgery, the radiation-related vasculopathies manifest as a late sequela. Lucas et al. reported no added radiotherapy-related risk of vascular morbidity in their patients [44]. However, further studies using screening for radiation-related vasculopathies are needed to evaluate the diagnostic value of routine MRA in aftercare. Furthermore, the clinical relevance of MRA-confirmed vasculopathies needs to be examined since many patients had abnormal angiographies but no symptoms or further complications.

Compared to previously published reviews, this scoping review identified and systematically summarized the available evidence regarding the quantity and different types of vascular damage in adult and pediatric patients with childhood- and adult-onset CP in existing case reports and observational studies. Jamshidi et al. reviewed the neurosurgical literature for FDCA after pediatric craniopharyngioma [95]. The authors also postulated that FDCA is a rare complication of CP surgery. If FDCA occurred, the course was innocuous, and no ruptures were described in the literature [95]. However, FDCA was the most frequently described complication among the studies included in our scoping review. Erfurth also reported the increased prevalence of hypertension, other cardiovascular morbidities, and MetS in CP patients in a narrative review [13]. CP patients more often receive treatment for CVD, as well as anti-hypertensive, anti-diabetes treatment, and lipid-lowering drugs. Steinbok reviewed the literature on cerebrovascular abnormalities in CP patients [9]. Linking cerebrovascular problems to surgery or radiotherapy, the author described the possibility of carotid pseudoaneurysm occurring as a result of surgery to remove a tumor adherent to the carotid artery. Furthermore, the author reported on internal carotid artery stenosis, middle cerebral artery stenosis, anterior cerebral artery stenosis, Moyamoya syndrome, stroke, and cavernoma caused by radiotherapy, consistent with our findings.

This scoping review has certain strengths and limitations. To the best of our knowledge, this is the first scoping review of the available evidence for vascular complications in childhood- and adult-onset craniopharyngioma patients. We used a broad systematic search of three databases and independently assessed the eligibility of studies by employing two reviewers. However, for language, our review was limited to articles published in German or English. Although this scope covers most scientific articles, we cannot rule out missing relevant information published in other languages. The data were extracted by one reviewer, potentially increasing the chance of missing details. Due to the disease’s rareness, the included evidence is limited to case reports, small sample sizes, and heterogeneous study groups.

5. Conclusions

In conclusion, vascular damage mostly occurs post-surgery or as a late side effect of radiotherapy in CP patients. Stroke, aneurysms, FDCA, and Moyamoya syndrome were the complications most commonly reported in the literature. While this review does not establish causality, it suggests a plausible association between vascular lesions and CP treatment, which should be taken into consideration in clinical practice. Prospective cohort studies are needed to assess the incidence of vascular sequela in this population. Furthermore, risk factors before and after CP treatment leading to vascular morbidity should be assessed in future studies. Target emulation trials are needed to compare the risk of vascular complications after different surgical approaches to treating CP. Follow-up care programs must consider the lifelong risk of CVD in CP patients. Tertiary prevention programs are required for CP survivors to reduce the risk of obesity-related cardiovascular events. In patients prone to neuro-cerebrovascular complications, especially after radiotherapy treatment, MRA should be applied at follow-up. Children who receive radiotherapy for CP early in life should be monitored regularly since they will experience decades of survival.

Author Contributions

Conceptualization, J.B. and C.F.; methodology, J.B.; software, J.B; formal analysis, J.B. and C.F.; investigation, J.B.; resources, J.B.; data curation, J.B.; writing—original draft preparation, J.B.; writing—review and editing, C.F. and H.L.M.; visualization, J.B.; supervision, C.F. and H.L.M.; project administration, H.L.M.; funding acquisition, H.L.M. All authors have read and agreed to the published version of the manuscript.

Conflicts of Interest

H.L.M. received reimbursement for participation fees paid for attending scientific meetings and continuing medical education events hosted by the following companies: Ferring, Lilly, Pfizer, Sandoz/Hexal, Novo Nordisk, IPSEN, and Merck Serono. H.L.M. received reimbursement of travel expenses from IPSEN and Rhythm and lecture honoraria from Pfizer and Rhythm. The other authors declare that they have no conflicts of interest. The funders had no role in the design of the study; the collection, analysis, or interpretation of data; the writing of the manuscript; or the decision to publish the results.

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Supplementary Materials

The following supporting information can be downloaded at https://www.mdpi.com/article/10.3390/cancers16061099/s1, Table S1: Data extraction table [8,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85,86,87,88,89,90,91,92,93]; Table S2: Details on studies assessing surgery and vascular complications [22,34,35,37,38,45,46,47,48,49,51,52,53,55,56,72,73,76,77,80,81,82,83,87,89,91,93]; Table S3: Details on studies assessing radiotherapy and vascular complications [8,30,36,42,43,44,54,57,58,59,60,61,63,64,65,67,68,69,70,71,74,75,78,79,84,88].

Appendix A

Search terms PUBMED: (“cardiovascular diseases”[MESH] OR “cerebrovascular disorders”[MESH] OR “cerebrovascular trauma”[MESH] OR “Moyamoya disease”[MESH] OR “Brain infarction”[MESH] OR “Myocardial infarction”[MESH]) OR vasculopathy AND (craniopharyngioma) Results: 488 on 19 June 2023

CINAHL via Ebsco Host: craniopharyngioma AND (“cerebrovascular disorders” OR “cardiovascular disease” OR “cerebrovascular trauma” OR “Moyamoya disease” OR “brain infarction” OR “myocardial infarction” OR vasculopathy) Results: 16 on 19 June 2023

Web of Science: (ALL = (craniopharyngioma)) AND ALL = (“cerebrovascular disorders” OR “cardiovascular disease” OR “cerebrovascular trauma” OR “Moyamoya disease” OR “brain infarction” OR “myocardial infarction” OR vasculopathy) Results: 52 on 19 June 2023

References

1. G.R. Bunin; T.S. Surawicz; P.A. Witman; S. Preston-Martin; F. Davis; J.M. Bruner The descriptive epidemiology of craniopharyngioma., 1998, 89,pp. 547-551. DOI: https://doi.org/10.3171/jns.1998.89.4.0547.

2. H.L. Müller; M. Tauber; E.A. Lawson; J. Özyurt; B. Bison; J.-P. Martinez-Barbera; S. Puget; T.E. Merchant; H.M. van Santen Hypothalamic syndrome., 2022, 8,p. 24. DOI: https://doi.org/10.1038/s41572-022-00351-z.

3. H.L. Muller; T.E. Merchant; M. Warmuth-Metz; J.P. Martinez-Barbera; S. Puget Craniopharyngioma., 2019, 5,p. 75. DOI: https://doi.org/10.1038/s41572-019-0125-9.

4. S. Santagata; T. Komori; H.L. Müller; T. Pietsch Adamantinomatous craniopharyngioma (Tumours of the sellar region)., 5th ed. edition; International Agency for Research on Cancer: Lyon, France, 2021, Volume 6,pp. 393-396.

5. K.L. Webb; W.W. Pruter; M.L. Hinkle; M.T. Walsh Comparing surgical approaches for craniopharyngioma resection among adults and children: A meta-analysis and systematic review., 2023, 175,pp. e876-e896. DOI: https://doi.org/10.1016/j.wneu.2023.04.037.

6. N.M. Alotaibi; G. Lanzino Cerebral vasospasm following tumor resection., 2013, 5,pp. 413-418. DOI: https://doi.org/10.1136/neurintsurg-2012-010477.

7. A. Bogusz; H.L. Muller Childhood-onset craniopharyngioma: Latest insights into pathology, diagnostics, treatment, and follow-up., 2018, 18,pp. 793-806. DOI: https://doi.org/10.1080/14737175.2018.1528874.

8. T.E. Merchant; M.E. Hoehn; R.B. Khan; N.D. Sabin; P. Klimo; F.A. Boop; S. Wu; Y. Li; E.A. Burghen; N. Jurbergs et al. Proton therapy and limited surgery for paediatric and adolescent patients with craniopharyngioma (RT2CR): A single-arm, phase 2 study., 2023, 24,pp. 523-534. DOI: https://doi.org/10.1016/S1470-2045(23)00146-8. PMID: https://www.ncbi.nlm.nih.gov/pubmed/37084748.

9. P. Steinbok Craniopharyngioma in Children: Long-term Outcomes., 2015, 55,pp. 722-726. DOI: https://doi.org/10.2176/nmc.ra.2015-0099. PMID: https://www.ncbi.nlm.nih.gov/pubmed/26345668.

10. R.M. Scott; J.L. Smith; R.L. Robertson; J.R. Madsen; S.G. Soriano; M.A. Rockoff Long-term outcome in children with moyamoya syndrome after cranial revascularization by pial synangiosis., 2004, 100,pp. 142-149. DOI: https://doi.org/10.3171/ped.2004.100.2.0142.

11. A.M. Daubenbuchel; H.L. Muller Neuroendocrine Disorders in Pediatric Craniopharyngioma Patients., 2015, 4,pp. 389-413. DOI: https://doi.org/10.3390/jcm4030389. PMID: https://www.ncbi.nlm.nih.gov/pubmed/26239246.

12. R.H. Lustig Hypothalamic obesity after craniopharyngioma: Mechanisms, diagnosis, and treatment., 2011, 2,p. 60. DOI: https://doi.org/10.3389/fendo.2011.00060.

13. E.M. Erfurth Endocrine aspects and sequel in patients with craniopharyngioma., 2015, 28,pp. 19-26. DOI: https://doi.org/10.1515/jpem-2014-0419.

14. H.M. Van Santen; J. van Schaik; I.M. van Roessel; J. Beckhaus; S. Boekhoff; H.L. Müller Diagnostic criteria for the hypothalamic syndrome in childhood., 2023, 188,pp. 214-225. DOI: https://doi.org/10.1093/ejendo/lvad009.

15. A. Umer; G.A. Kelley; L.E. Cottrell; P. Giacobbi; K.E. Innes; C.L. Lilly Childhood obesity and adult cardiovascular disease risk factors: A systematic review with meta-analysis., 2017, 17, 683. DOI: https://doi.org/10.1186/s12889-017-4691-z.

16. H.L. Muller; T.E. Merchant; S. Puget; J.P. Martinez-Barbera New outlook on the diagnosis, treatment and follow-up of childhood-onset craniopharyngioma., 2017, 13,pp. 299-312. DOI: https://doi.org/10.1038/nrendo.2016.217.

17. E.H. Yang; K. Marmagkiolis; D.V. Balanescu; A. Hakeem; T. Donisan; W. Finch; R. Virmani; J. Herrman; M. Cilingiroglu; C.L. Grines et al. Radiation-Induced Vascular Disease—A State-of-the-Art Review., 2021, 8,p. 652761. DOI: https://doi.org/10.3389/fcvm.2021.652761. PMID: https://www.ncbi.nlm.nih.gov/pubmed/33860001.

18. S. Mong; S.L. Pomeroy; F. Cecchin; A. Juraszek; M.E. Alexander Cardiac risk after craniopharyngioma therapy., 2008, 38,pp. 256-260. DOI: https://doi.org/10.1016/j.pediatrneurol.2007.11.007. PMID: https://www.ncbi.nlm.nih.gov/pubmed/18358404.

19. C.L. Roth; H. Eslamy; D. Werny; C. Elfers; M.L. Shaffer; C. Pihoker; J. Ojemann; W.B. Dobyns Semiquantitative analysis of hypothalamic damage on MRI predicts risk for hypothalamic obesity., 2015, 23,pp. 1226-1233. DOI: https://doi.org/10.1002/oby.21067. PMID: https://www.ncbi.nlm.nih.gov/pubmed/25884561.

20. H.L. Muller Childhood craniopharyngioma—Current concepts in diagnosis, therapy and follow-up., 2010, 6,pp. 609-618. DOI: https://doi.org/10.1038/nrendo.2010.168. PMID: https://www.ncbi.nlm.nih.gov/pubmed/20877295.

21. M.D.J. Peters; C. Marnie; A.C. Tricco; D. Pollock; Z. Munn; L. Alexander; P. McInerney; C.M. Godfrey; H. Khalil Updated methodological guidance for the conduct of scoping reviews., 2021, 19,pp. 3-10. DOI: https://doi.org/10.1097/XEB.0000000000000277. PMID: https://www.ncbi.nlm.nih.gov/pubmed/33570328.

22. S. Boekhoff; B. Bison; D. Genzel; M. Eveslage; A. Otte; C. Friedrich; J. Flitsch; H.L. Müller Cerebral Infarction in Childhood-Onset Craniopharyngioma Patients: Results of KRANIOPHARYNGEOM 2007., 2021, 11,p. 698150. DOI: https://doi.org/10.3389/fonc.2021.698150. PMID: https://www.ncbi.nlm.nih.gov/pubmed/34336685.

23. F. Ferraù; F. Spagnolo; O.R. Cotta; L. Cannavò; A. Alibrandi; G.T. Russo; T. Aversa; F. Trimarchi; S. Cannavò Visceral adiposity index as an indicator of cardiometabolic risk in patients treated for craniopharyngioma., 2017, 58,pp. 295-302. DOI: https://doi.org/10.1007/s12020-016-1196-y.

24. H.W. Jung; H.Y. Kim; J.Y. Kim; J.E. Cheon; I.O. Kim; S.K. Kim; C.H. Shin; S.W. Yang; Y.A. Lee Autonomic Dysfunction is Associated with Increased Cardiometabolic Risk in Patients with Childhood-Onset Craniopharyngioma., 2020, 52,pp. 500-508. DOI: https://doi.org/10.1055/a-1169-0307. PMID: https://www.ncbi.nlm.nih.gov/pubmed/32512610.

25. P. Sowithayasakul; L.K. Buschmann; S. Boekhoff; H.L. Muller Cardiac remodeling in patients with childhood-onset craniopharyngioma—Results of HIT-Endo and KRANIOPHARYNGEOM 2000/2007., 2021, 180,pp. 1593-1602. DOI: https://doi.org/10.1007/s00431-020-03915-x. PMID: https://www.ncbi.nlm.nih.gov/pubmed/33459867.

26. H. Holmer; B. Ekman; J. Bjork; C.H. Nordstom; V. Popovic; A. Siversson; E.M. Erfurth Hypothalamic involvement predicts cardiovascular risk in adults with childhood onset craniopharyngioma on long-term GH therapy., 2009, 161,pp. 671-679. DOI: https://doi.org/10.1530/EJE-09-0449.

27. H.W. Jung; H.Y. Kim; J.Y. Kim; J.E. Cheon; I.O. Kim; S.K. Kim; C.H. Shin; S.W. Yang; Y.A. Lee Cardiac autonomic dysfunction is associated with hypothalamic damage in patients with childhood-onset craniopharyngioma., 2021, 16, e0246789. DOI: https://doi.org/10.1371/journal.pone.0246789.

28. T. Verweij; T.N.A. Slagboom; N.C. van Varsseveld; A.J. van der Lely; M.L. Drent; C.C. van Bunderen Cardiovascular risk profile in growth hormone-treated adults with craniopharyngioma compared to non-functioning pituitary adenoma: A national cohort study., 2021, 185,pp. 793-801. DOI: https://doi.org/10.1530/EJE-21-0419.

29. A.M. Pereira; E.M. Schmid; P.J. Schutte; J.H.C. Voormolen; N.R. Biermasz; S.W. van Thiel; E.P.M. Corssmit; J.W.A. Smit; F. Roelfsema; J.A. Romijn High prevalence of long-term cardiovascular, neurological and psychosocial morbidity after treatment for craniopharyngioma., 2005, 62,pp. 197-204. DOI: https://doi.org/10.1111/j.1365-2265.2004.02196.x.

30. S. Sarkar; S. Korula; S. Mathai; A. Simon; R. Balakrishnan; S. Backianathan; A.G. Chacko Upfront adjuvant irradiation versus postoperative surveillance following incomplete surgical resection of craniopharyngiomas in children and young adults., 2022, 38,pp. 1877-1883. DOI: https://doi.org/10.1007/s00381-022-05635-z.

31. B. Bülow; R. Attewell; L. Hagmar; P. Malmström; C.H. Nordström; E.M. Erfurth Postoperative prognosis in craniopharyngioma with respect to cardiovascular mortality, survival, and tumor recurrence., 1998, 83,pp. 3897-3904. DOI: https://doi.org/10.1210/jc.83.11.3897.

32. D.S. Olsson; E. Andersson; I.L. Bryngelsson; A.G. Nilsson; G. Johannsson Excess Mortality and Morbidity in Patients with Craniopharyngioma, Especially in Patients with Childhood Onset: A Population-Based Study in Sweden., 2015, 100,pp. 467-474. DOI: https://doi.org/10.1210/jc.2014-3525.

33. M. Wijnen; D.S. Olsson; M.M. van den Heuvel-Eibrink; C. Hammarstrand; J. Janssen; A.J. van der Lely; G. Johannsson; S. Neggers Excess morbidity and mortality in patients with craniopharyngioma: A hospital-based retrospective cohort study., 2018, 178,pp. 93-102. DOI: https://doi.org/10.1530/EJE-17-0707.

34. N. Qiao; Q. Zhang; L. Chen; W. He; Z. Ma; Z. Ye; M. He; Z. Zhang; X. Zhou; M. Shen et al. Machine learning prediction of venous thromboembolism after surgeries of major sellar region tumors., 2023, 226,pp. 1-8. DOI: https://doi.org/10.1016/j.thromres.2023.04.007.

35. A. Hoffmann; M. Warmuth-Metz; K. Lohle; J. Reichel; A.M. Daubenbüchel; A.S. Sterkenburg; H.L. Müller Fusiform dilatation of the internal carotid artery in childhood-onset craniopharyngioma: Multicenter study on incidence and long-term outcome., 2016, 19,pp. 422-428. DOI: https://doi.org/10.1007/s11102-016-0722-5.

36. U. Sandvik; M. Ohlsson; E. Edström Vascular complications in pediatric craniopharyngioma patients: A case-based update., 2019, 35,pp. 2273-2278. DOI: https://doi.org/10.1007/s00381-019-04394-8.

37. L.N. Sutton Vascular complications of surgery for craniopharyngioma and hypothalamic glioma., 1994, 21,pp. 124-128. DOI: https://doi.org/10.1159/000120874.

38. W. Tirakotai; U. Sure; L. Benes; H. Aboul-Enein; D.M. Schulte; T. Riegel; H. Bertalanffy Successful management of a symptomatic fusiform dilatation of the internal carotid artery following surgery of childhood craniopharyngioma., 2002, 18,pp. 717-721. DOI: https://doi.org/10.1007/s00381-002-0666-0. PMID: https://www.ncbi.nlm.nih.gov/pubmed/12483358.

39. H. Nishioka; H. Ito; J. Haraoka; T. Hashimoto; Y. Kato Repeated hemorrhage in ciliated craniopharyngioma—Case report., 2000, 40,pp. 324-328. DOI: https://doi.org/10.2176/nmc.40.324.

40. S. Yamashita; Y. Matsumoto; K. Kunishio; S. Nagao Craniopharyngiomas with intratumoral hemorrhage—Two case reports., 2004, 44,pp. 43-46. DOI: https://doi.org/10.2176/nmc.44.43. PMID: https://www.ncbi.nlm.nih.gov/pubmed/14959937.

41. L. Becker; J. Gebauer; J. Küchler; C. Staackmann; H. Schacht; M. Lauten; U. Jensen-Kondering; P. Schramm; T. Langer; A. Neumann Are radiation-induced cavernomas clinically relevant findings? Results from long-term follow-up with brain magnetic resonance imaging of childhood cancer survivors., 2021, 55,pp. 274-283. DOI: https://doi.org/10.2478/raon-2021-0032. PMID: https://www.ncbi.nlm.nih.gov/pubmed/34384013.

42. V. Strenger; P. Sovinz; H. Lackner; H.J. Dornbusch; H. Lingitz; H.G. Eder; A. Moser; C. Urban Intracerebral cavernous hemangioma after cranial irradiation in childhood. Incidence and risk factors., 2008, 184,pp. 276-280. DOI: https://doi.org/10.1007/s00066-008-1817-3. PMID: https://www.ncbi.nlm.nih.gov/pubmed/18427759.

43. A.K. Liu; B. Bagrosky; L.Z. Fenton; L.E. Gaspar; M.H. Handler; S.A. McNatt; N.K. Foreman Vascular abnormalities in pediatric craniopharyngioma patients treated with radiation therapy., 2009, 52,pp. 227-230. DOI: https://doi.org/10.1002/pbc.21787. PMID: https://www.ncbi.nlm.nih.gov/pubmed/18937328.

44. J.T. Lucas; A.M. Faught; C.Y. Hsu; L.J. Wilson; Y. Guo; Y. Li; R. Khan; J.B. Becksfort; D.A. LeVine; Y. Ismael et al. Pre- and Posttherapy Risk Factors for Vasculopathy in Pediatric Patients with Craniopharyngioma Treated with Surgery and Proton Radiation Therapy., 2022, 113,pp. 152-160. DOI: https://doi.org/10.1016/j.ijrobp.2021.12.172. PMID: https://www.ncbi.nlm.nih.gov/pubmed/34990778.

45. Q. Li; C. Wang; J. Xu; C. You Endovascular Treatment for Fusiform Dilation of Internal Carotid Artery Following Craniopharyngioma Resection: A Case Illustration., 2015, 30,pp. 1354-1356. DOI: https://doi.org/10.1177/0883073814552105.

46. I. Linfante; C. Tucci; V. Andreone Fusiform dilatation of the internal carotid artery after craniopharyngioma resection., 2008, 39,pp. 139-140. DOI: https://doi.org/10.1016/j.pediatrneurol.2008.04.001.

47. S.S. Liu; J.M. Zabramski; R.F. Spetzler Fusiform aneurysm after surgery for craniopharyngioma., 1991, 75,pp. 670-672. DOI: https://doi.org/10.3171/jns.1991.75.4.0670a.

48. T. Nagata; T. Goto; T. Ichinose; Y. Mitsuhashi; N. Tsuyuguchi; K. Ohata Pathological findings of fusiform dilation of the internal carotid artery following radical dissection of a craniopharyngioma., 2010, 6,pp. 567-571. DOI: https://doi.org/10.3171/2010.9.PEDS10280.

49. L.N. Sutton; D. Gusnard; D.A. Bruce; A. Fried; R.J. Packer; R.A. Zimmerman Fusiform dilatations of the carotid artery following radical surgery of childhood craniopharyngiomas., 1991, 74,pp. 695-700. DOI: https://doi.org/10.3171/jns.1991.74.5.0695.

50. S. Takeuchi; K. Wada; F. Sakakibara; H. Nawashiro; K. Mori Anterior cerebral artery dissecting aneurysm associated with untreated craniopharyngioma., 2013, 27,pp. 102-104. DOI: https://doi.org/10.3109/02688697.2012.701677.

51. L. Wang; X. Shi; F. Liu; H. Qian Bypass surgery to treat symptomatic fusiform dilation of the internal carotid artery following craniopharyngioma resection: Report of 2 cases., 2016, 41,p. E17. DOI: https://doi.org/10.3171/2016.9.FOCUS16252.

52. R. Aboukaïs; M. Bretonnier; M.A. Karnoub; X. Leclerc; L. Riffaud; J.P. Lejeune; M. Vinchon Fusiform dilatation of internal carotid artery after pterional but not subfrontal craniotomy in 6 patients., 2021, 37,pp. 125-129. DOI: https://doi.org/10.1007/s00381-020-04753-w.

53. R.E. Elliott; J.H. Wisoff Fusiform dilation of the carotid artery following radical resection of pediatric craniopharyngiomas: Natural history and management., 2010, 28,p. E14. DOI: https://doi.org/10.3171/2010.1.FOCUS09296.

54. M.D. Hall; J.A. Bradley; R.L. Rotondo; R. Hanel; C. Shah; C.G. Morris; P.R. Aldana; D.J. Indelicato Risk of Radiation Vasculopathy and Stroke in Pediatric Patients Treated With Proton Therapy for Brain and Skull Base Tumors., 2018, 101,pp. 854-859. DOI: https://doi.org/10.1016/j.ijrobp.2018.03.027.

55. R. Nash; V. Elwell; S. Brew; M. Powell; J.P. Grieve Management strategy for treatment of vasospasm following transsphenoidal excision of craniopharyngioma., 2016, 158,pp. 2105-2108. DOI: https://doi.org/10.1007/s00701-016-2956-4.

56. A. Singh; P. Salunke; V. Rangan; C.K. Ahuja; S. Bhadada Vasospasm After Craniopharyngioma Surgery: Can We Prevent It?., 2017, 101,pp. 208-215. DOI: https://doi.org/10.1016/j.wneu.2017.01.115.

57. A. Bolsi; L. Placidi; A. Pica; F.J. Ahlhelm; M. Walser; A.J. Lomax; D.C. Weber Pencil beam scanning proton therapy for the treatment of craniopharyngioma complicated with radiation-induced cerebral vasculopathies: A dosimetric and linear energy transfer (LET) evaluation., 2020, 149,pp. 197-204. DOI: https://doi.org/10.1016/j.radonc.2020.04.052.

58. H. Gleeson; R. Amin; M. Maghnie ‘Do no harm’: Management of craniopharyngioma., 2008, 159,pp. S95-S99. DOI: https://doi.org/10.1530/EJE-08-0400. PMID: https://www.ncbi.nlm.nih.gov/pubmed/18775978.

59. Y. Kato; M. Fujimura; K. Sato; H. Endo; T. Tominaga Efficacy of Direct Revascularization Surgery for Hemorrhagic Moyamoya Syndrome as a Late Complication of Cranial Irradiation for Childhood Craniopharyngioma., 2019, 28,pp. e46-e50. DOI: https://doi.org/10.1016/j.jstrokecerebrovasdis.2019.01.033.

60. K.A. Lee; C. O’Sullivan; P. Daly; J. Pears; C. Owens; B. Timmermann; C. Ares; S.E. Combs; D. Indelicato; M. Capra Proton therapy in paediatric oncology: An Irish perspective., 2017, 186,pp. 577-582. DOI: https://doi.org/10.1007/s11845-016-1520-9. PMID: https://www.ncbi.nlm.nih.gov/pubmed/27744643.

61. M.R. Reynolds; D.H. Haydon; J. Caird; J.R. Leonard Radiation-Induced Moyamoya Syndrome after Proton Beam Therapy in the Pediatric Patient: A Case Series., 2016, 51,pp. 297-301. DOI: https://doi.org/10.1159/000446075. PMID: https://www.ncbi.nlm.nih.gov/pubmed/27193755.

62. K. Ujifuku; T. Matsuo; T. Takeshita; Y. Hayashi; K. Hayashi; N. Kitagawa; T. Hayashi; K. Suyama; I. Nagata Malignant transformation of craniopharyngioma associated with moyamoya syndrome., 2010, 50,pp. 599-603. DOI: https://doi.org/10.2176/nmc.50.599.

63. J. Visser; J. Hukin; M. Sargent; P. Steinbok; K. Goddard; C. Fryer Late mortality in pediatric patients with craniopharyngioma., 2010, 100,pp. 105-111. DOI: https://doi.org/10.1007/s11060-010-0145-5.

64. Y.H. Wu; F.C. Chang; M.L. Liang; H.H. Chen; T.T. Wong; S.H. Yen; Y.W. Chen Incidence and long-term outcome of postradiotherapy moyamoya syndrome in pediatric patients with primary brain tumors: A single institute experience in Taiwan., 2016, 5,pp. 2155-2160. DOI: https://doi.org/10.1002/cam4.785. PMID: https://www.ncbi.nlm.nih.gov/pubmed/27265024.

65. C.H. Zhang; W. Muirhead; A.H.D. Silva; C. Toolis; F. Robertson; A. Rennie; S. Bhate; D.N.P. Thompson; V. Ganesan; G. James Neurosurgical management of proton beam therapy-induced moyamoya syndrome., 2023, 31,pp. 369-379. DOI: https://doi.org/10.3171/2022.12.PEDS22423. PMID: https://www.ncbi.nlm.nih.gov/pubmed/36738468.

66. G. Zuccaro; R. Jaimovich; B. Mantese; J. Monges Complications in paediatric craniopharyngioma treatment., 1996, 12,pp. 385-390. DOI: https://doi.org/10.1007/BF00395090.

67. M. Bitzer; H. Topka Progressive cerebral occlusive disease after radiation therapy., 1995, 26,pp. 131-136. DOI: https://doi.org/10.1161/01.STR.26.1.131. PMID: https://www.ncbi.nlm.nih.gov/pubmed/7839383.

68. P. Almeida; A.L. Rocha; G. Alves; T. Parreira; M.L. Silva; A. Cerejo; P. Abreu; A. Monteiro Moyamoya Syndrome after Radiation Therapy: A Clinical Report., 2019, 6,p. 001337. DOI: https://doi.org/10.12890/2019_001337.

69. H.S. Lee; H.J. Seol; D.S. Kong; H.J. Shin Moyamoya Syndrome Precipitated by Cranial Irradiation for Craniopharyngioma in Children., 2011, 50,pp. 535-537. DOI: https://doi.org/10.3340/jkns.2011.50.6.535. PMID: https://www.ncbi.nlm.nih.gov/pubmed/22323944.

70. V.M. Ravindra; M.F. Okcu; L. Ruggieri; T.S. Frank; A.C. Paulino; S.L. McGovern; V.E. Horne; R.C. Dauser; W.E. Whitehead; G. Aldave Comparison of multimodal surgical and radiation treatment methods for pediatric craniopharyngioma: Long-term analysis of progression-free survival and morbidity., 2021, 28,pp. 152-159. DOI: https://doi.org/10.3171/2020.11.PEDS20803.

71. I.S. Boon; D. Perera; J. Ayuk When Occam’s razor fails: Hemipontine infarct on a background of previous surgery and radiotherapy for craniopharyngioma., 2016, 2016,p. bcr2016215420. DOI: https://doi.org/10.1136/bcr-2016-215420.

72. W.S. Cho; S.K. Kim; K.C. Wang; J.H. Phi; B.K. Cho Vasculopathy after intracystic bleomycin administration for a recurrent cystic craniopharyngioma: Case report., 2012, 9,pp. 394-399. DOI: https://doi.org/10.3171/2012.1.PEDS11437. PMID: https://www.ncbi.nlm.nih.gov/pubmed/22462704.

73. B. Fischer; S. Palkovic; D. Schildheuer; W. Heindel; H. Wassmann Inflammatory thromboembolic complication after craniopharyngioma surgery?., 2004, 146,pp. 183-186. DOI: https://doi.org/10.1007/s00701-003-0178-z. PMID: https://www.ncbi.nlm.nih.gov/pubmed/14963754.

74. W.G. Mitchell; L.S. Fishman; J.H. Miller; M. Nelson; P.M. Zeltzer; D. Soni; S.M. Siegel Stroke as a late sequela of cranial irradiation for childhood brain tumors., 1991, 6,pp. 128-133. DOI: https://doi.org/10.1177/088307389100600206. PMID: https://www.ncbi.nlm.nih.gov/pubmed/2045628.

75. A.C. Lo; A.F. Howard; A. Nichol; H. Hasan; M. Martin; M. Heran; K. Goddard A Cross-Sectional Cohort Study of Cerebrovascular Disease and Late Effects After Radiation Therapy for Craniopharyngioma., 2016, 63,pp. 786-793. DOI: https://doi.org/10.1002/pbc.25889. PMID: https://www.ncbi.nlm.nih.gov/pubmed/26756999.

76. C. Koumas; A. Laibangyang; S.L. Barron; M.A. Mittler; S.J. Schneider; S.D. Rodgers Outcomes following endoscopic endonasal resection of sellar and supresellar lesions in pediatric patients., 2019, 35,pp. 2099-2105. DOI: https://doi.org/10.1007/s00381-019-04258-1.

77. I.F. Ricarte; B.F. Funchal; M.A. Miranda Alves; D.L. Gomes; R.A. Valiente; F.A. Carvalho; G.S. Silva Symptomatic Cerebral Vasospasm and Delayed Cerebral Ischemia Following Transsphenoidal Resection of a Craniopharyngioma., 2015, 24,pp. e271-e273. DOI: https://doi.org/10.1016/j.jstrokecerebrovasdis.2015.06.005. PMID: https://www.ncbi.nlm.nih.gov/pubmed/26198371.

78. D.Y. Edmonston; S. Wu; Y. Li; R.B. Khan; F.A. Boop; T.E. Merchant Limited surgery and conformal photon radiation therapy for pediatric craniopharyngioma: Long-term results from the RT1 protocol., 2022, 24,pp. 2200-2209. DOI: https://doi.org/10.1093/neuonc/noac124.

79. D.J. Indelicato; J.A. Bradley; E.S. Sandler; P.R. Aldana; A. Sapp; J.E. Gains; A. Crellin; R.L. Rotondo Clinical outcomes following proton therapy for children with central nervous system tumors referred overseas., 2017, 64,p. e26654. DOI: https://doi.org/10.1002/pbc.26654.

80. N. Fukuhara; H. Nishioka; S. Yamada Acute Subdural Hematoma Immediately After Extended Transsphenoidal Surgery for Craniopharyngioma., 2017, 27,pp. 309-311. DOI: https://doi.org/10.5137/1019-5149.Jtn.12717-14.2.

81. J. Yu; H. Yang; D. Cui; Y. Li Retrospective analysis of 14 cases of remote epidural hematoma as a postoperative complication after intracranial tumor resection., 2016, 14,p. 1. DOI: https://doi.org/10.1186/s12957-015-0754-8.

82. R.L. Macdonald; H.J. Hoffman Subarachnoid hemorrhage and vasospasm following removal of craniopharyngioma., 1997, 4,pp. 348-352. DOI: https://doi.org/10.1016/S0967-5868(97)90104-1.

83. M.A. Jamaluddin; R.D. Rangnekar; G.C. Vilanilam; G. Garhwal; M. Abraham Visual Deterioration Due to Unruptured Saccular Internal Carotid Artery Aneurysm in an Operated Case of Craniopharyngioma., 2020, 68,pp. 1250-1252. DOI: https://doi.org/10.4103/0028-3886.299169.

84. P. Pereira; A. Cerejo; J. Cruz; R. Vaz Intracranial aneurysm and vasculopathy after surgery and radiation therapy for craniopharyngioma: Case report., 2002, 50,pp. 885-887. DOI: https://doi.org/10.1097/00006123-200204000-00042. PMID: https://www.ncbi.nlm.nih.gov/pubmed/11904045.

85. M.B. Pritz Ruptured true posterior communicating artery aneurysm and cystic craniopharyngioma., 2002, 144,pp. 937-939. DOI: https://doi.org/10.1007/s00701-002-0943-4.

86. H. Qian; L. Wang; K.S. Brooks; X. Zhao; F. Liu; Y. Sun; X. Shi; T. Lei Intraoperative Finding of an Anterior Communicating Artery Blister-Like Aneurysm during a Primary Craniopharyngioma Resection: Accidental or Incidental?., 2019, 127,pp. 514-517. DOI: https://doi.org/10.1016/j.wneu.2019.04.067.

87. L.M. Cavallo; D. Solari; F. Esposito; P. Cappabianca The endoscopic endonasal approach for the management of craniopharyngiomas involving the third ventricle., 2013, 36,pp. 27-37. DOI: https://doi.org/10.1007/s10143-012-0403-4.

88. S.F. Kralik; G.A. Watson; C.S. Shih; C.Y. Ho; W. Finke; J. Buchsbaum Radiation-Induced Large Vessel Cerebral Vasculopathy in Pediatric Patients With Brain Tumors Treated With Proton Radiation Therapy., 2017, 99,pp. 817-824. DOI: https://doi.org/10.1016/j.ijrobp.2017.07.009.

89. S.K. Lakhanpal; C.M. Glasier; C.A. James; E.J. Angtuaco MR and CT diagnosis of carotid pseudoaneurysm in children following surgical resection of craniopharyngioma., 1995, 25,pp. 249-251. DOI: https://doi.org/10.1007/BF02011088. PMID: https://www.ncbi.nlm.nih.gov/pubmed/7567226.

90. M.M. Hawkins; J.E. Kingston; L.M.K. Wilson; L.M. Kinnier Wilson Late deaths after treatment for childhood cancer., 1990, 65,pp. 1356-1363. DOI: https://doi.org/10.1136/adc.65.12.1356. PMID: https://www.ncbi.nlm.nih.gov/pubmed/2270944.

91. C. Probst Heart arrest in excision of large craniopharyngiomas: Two cases with successful resuscitation—Pathogenic considerations., 1992, 35,pp. 9-13. DOI: https://doi.org/10.1055/s-2008-1052237.

92. S. Chandrakasan; S. Sood; S. Ham; K. Moltz; M.J. Frey; M. Rajpurkar Risk factors and management of deep venous thrombosis in children following post-surgical hypopituitarism in craniopharyngioma., 2011, 57,pp. 175-177. DOI: https://doi.org/10.1002/pbc.22937. PMID: https://www.ncbi.nlm.nih.gov/pubmed/21557464.

93. W.A. Lambert; M. Paro; E. Pinci; M.J. Bookland; J.E. Martin; R. Riba-Wolman; L. McKay; D.S. Hersh Venous thromboembolism in the setting of pediatric central diabetes insipidus: A systematic review of the literature and report of 2 cases., 2022, 29,pp. 580-589. DOI: https://doi.org/10.3171/2022.1.PEDS21469.

94. J. Beckhaus; C. Friedrich; S. Boekhoff; G. Calaminus; B. Bison; M. Eveslage; B. Timmermann; J. Flitsch; H.L. Müller Outcome after pediatric craniopharyngioma—The role of age at diagnosis and hypothalamic damage., 2023, 188,pp. 300-309. DOI: https://doi.org/10.1093/ejendo/lvad027. PMID: https://www.ncbi.nlm.nih.gov/pubmed/36857103.

95. A.M. Jamshidi; S. Soldozy; T. Elarjani; J.D. Burks; E. Luther; R.M. Starke Fusiform Dilatation of the Internal Carotid Artery in Childhood-Onset Craniopharyngioma: A Systematic Review., 2022, 162,pp. 77-84. DOI: https://doi.org/10.1016/j.wneu.2021.09.058. PMID: https://www.ncbi.nlm.nih.gov/pubmed/34555575.

Figures and Tables

Figure 1: PRISMA flow chart outlining the study selection process. [Please download the PDF to view the image]

Figure 2: The number of published cases with neurovascular complications related to different etiologies. Abbreviations: FDCA: fusiform dilation of the carotid artery; TIA: transient ischemic attack. [Please download the PDF to view the image]

Figure 3: Short-, medium-, and long-term vascular complications reported due to the use of surgery and radiotherapy for treating craniopharyngioma. [Please download the PDF to view the image]

Table 1: Eligibility criteria for record assessment process.

PCC Framework	Definition
Population	Patients with adamantinomatous or papillary CP with any age at diagnosis
Concept	Vascular damages, cerebro- and cardiovascular diseases, incidence, disease-specific mortality, risk factors, and outcome
Context	Case reports and observational studies published since 1990 in English or German

Author Affiliation(s):

[1] Department of Pediatrics and Pediatric Hematology/Oncology, University Children’s Hospital, Carl von Ossietzky Universität Oldenburg, Klinikum Oldenburg AöR, 26133 Oldenburg, Germany; [email protected] (J.B.); [email protected] (C.F.)

[2] Division of Epidemiology and Biometry, Carl von Ossietzky Universität Oldenburg, 26129 Oldenburg, Germany

Author Note(s):

[*] Correspondence: [email protected]; Tel.: +49-441-403-2012

DOI: 10.3390/cancers16061099

Article Details

Printer friendly Cite/link Email Feedback
Author:	Beckhaus, Julia; Friedrich, Carsten; Müller, Hermann L.
Publication:	Cancers
Geographic Code:	4EUGE
Date:	Mar 1, 2024
Words:	8368
Previous Article:	Local Treatment of Colorectal Liver Metastases in the Presence of Extrahepatic Disease: Survival Outcomes from the Amsterdam Colorectal Liver Met...
Next Article:	Machine Learning Meets Cancer.
Topics:	Aneurysm Aneurysms Brain tumors Medical research Medicine, Experimental Morbidity Mortality Germany Pituitary gland tumors Pituitary tumors Radiotherapy Stroke Stroke (Disease)